Tiziana Life Sciences – Announces Plants to List Accustem Sciences in the US April 13, 2021 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders. The board of directors of…

Tiziana Life Sciences – Exercise of Warrants & Issue of Equity & Total Voting Rights July 24, 2020 – Posted in: Uncategorized

24th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 24 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 88,580 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of…

Tiziana Life Sciences – Interview to Air on Bloomberg Intl July 10, 2020 – Posted in: Tiziana Life Sciences (TILS)

10 July 2020 Tiziana Life Sciences plc Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with Kunwar Shailubhai, Ph.D., the Company’s CEO and CSO, will air on The RedChip Money Report television program. The interview will air Sunday,…

Tiziana Life Sciences – Totoal Voting Rights & StemPrintER Demerger Update July 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Wednesday 1st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Total Voting Rights and StemPrintER Demerger Update London, New York, 1 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that plans to effect the demerger of StemPrintER from the Group are continuing to be progressed and…

Tiziana Life Sciences #TILS – Appoints Optiva Securities Limited as Broker June 1, 2020 – Posted in: Uncategorized

Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effect. Enquiries: Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner …

Tiziana Life Sciences #TILS presents StemPrintER, a superior prognostic test compared to Oncotype DX to predict breast cancer May 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer · StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients · SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis New York/London – May 29, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

Tiziana Life Sciences #TILS – Demerger of StemPrintER Genomics-Based Personalized Medicine business as a separate listed company May 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, May 22, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER and SPARE (together “StemPrintER”) genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. Following the Company’s recent announcement concerning the…

Tiziana Life Sciences #TILS – Exercise of Warrants and Issue of Equity May 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 264,286 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of the exercise of 264,286 warrants at…

Tiziana Life Sciences #TILS – Online Publication of Two Abstracts at ASCO Reporting Clinical Activity & Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma May 14, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, May 14, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases , today announces the online publication of two abstracts on clinical studies with Milciclib, a small molecule pan-inhibitor of cyclin dependent kinases (CDKs) in the proceedings of the virtual annual meeting of American Society of Clinical Oncology 2020 (ASCO20) The first abstract…

Alan Green talks markets, Tiziana Life Sciences #TILS, Blue Prism #PRSM & Tertiary Minerals #TYM on UK Investor Mag podcast – Posted in: Tiziana Life Sciences (TILS)

Alan Green discusses markets, Tiziana Life Sciences #TILS, Blue Prism #PRSM & Tertiary Minerals #TYM with Jonathan Roy on the UK Investor Mag podcast. Link on the image to listen.

1
2
3
4
5
...
7
Next
Last »